BNP Paribas Asset Management
IOVA icon

BNP Paribas Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

BNP Paribas Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1K Buy
4,298
+1,102
+34% +$3.52K ﹤0.01% 2102
2025
Q4 		$9K Buy
3,196
+976
+44% +$2.26K ﹤0.01% 2172
2025
Q3 		$5K Buy
+2,220
New +$5.24K ﹤0.01% 1828

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

BNP Paribas Asset Management's IOVA Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Iovance Biotherapeutics (IOVA) stake by 34% in Q1 2026, buying an estimated $3.52K and bringing the position to 4,298 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2102.

BNP Paribas Asset Management first reported a position in IOVA in Q3 2025 and has held it in 3 quarters since. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • BNP Paribas Asset Management held 4,298 shares of Iovance Biotherapeutics worth $15.1K as of Q1 2026.
  • BNP Paribas Asset Management bought 1,102 Iovance Biotherapeutics shares in Q1 2026, an estimated $3.52K.
  • Iovance Biotherapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2102 holding.
  • BNP Paribas Asset Management first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.